Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,808 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disparities in Electronic Cigarette Use: A Narrative Review.
Edwards K, Manoharan A, Asfar T, Kareff S, Lopes G, Rodriguez E, Olazagasti C. Edwards K, et al. Among authors: rodriguez e. Crit Rev Oncog. 2024;29(3):91-98. doi: 10.1615/CritRevOncog.2024051128. Crit Rev Oncog. 2024. PMID: 38683156 Review.
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.
Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, Graff SL, Antonarakis ES, Goel S, Sledge G, Lopes G. Kareff SA, et al. Among authors: rodriguez e. Cancers (Basel). 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. Cancers (Basel). 2024. PMID: 38672653 Free PMC article.
Adaptive immune changes associate with clinical progression of Alzheimer's disease.
van Olst L, Kamermans A, Halters S, van der Pol SMA, Rodriguez E, Verberk IMW, Verberk SGS, Wessels DWR, Rodriguez-Mogeda C, Verhoeff J, Wouters D, Van den Bossche J, Garcia-Vallejo JJ, Lemstra AW, Witte ME, van der Flier WM, Teunissen CE, de Vries HE. van Olst L, et al. Among authors: rodriguez e. Mol Neurodegener. 2024 Apr 24;19(1):38. doi: 10.1186/s13024-024-00726-8. Mol Neurodegener. 2024. PMID: 38658964 Free PMC article.
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J, Rodriguez E, Maitland ML, Tsai FY, Socinski MA, Berlin JD, Thomas JS, Al Baghdadi T, Wang IM, Guo C, Golmakani M, Clark LN, Gazdoiu M, Li M, Tolcher AW. Rodon J, et al. Among authors: rodriguez e. ESMO Open. 2024 Apr 18;9(4):102961. doi: 10.1016/j.esmoop.2024.102961. Online ahead of print. ESMO Open. 2024. PMID: 38640748 Free PMC article.
3,808 results